The appetite suppressant d-fenfluramine reduces water intake, but not food intake, in activity-based anorexia

Journal of Molecular Endocrinology

Volumn 36, Issue 1, 2006, Pages 153-162

  Hillebrand, J J G ^a,b   Heinsbroek, A C M ^a   Kas, M J H ^a   Adan, R A H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Altrecht Rintveld Eating Disorders   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DEXFENFLURAMINE; MELANOCORTIN; SEROTONIN 2C RECEPTOR; VASOPRESSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARCUATE NUCLEUS; ARTICLE; BRAIN NERVE CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FLUID INTAKE; FOOD INTAKE; GENE ACTIVATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHERMIA; HYPOTHESIS; NONHUMAN; PLASMA OSMOLALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STARVATION; WEIGHT REDUCTION;

ANIMALS; ANOREXIA; APPETITE DEPRESSANTS; DRINKING BEHAVIOR; ENERGY INTAKE; FEMALE; FENFLURAMINE; IN SITU HYBRIDIZATION; MOTOR ACTIVITY; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; WATER;

EID: 33244460054     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.1.01887     Document Type: Article

References (65)

1. Altemus M, Glowa JR, Galliven E, Leong YM & Murphy DL 1996 Effects of Serotonergic Agents on Food-Restriction-Induced Hyperactivity. Pharmacology & Biochemistry of Behaviour 53 123-131.
2. Amaya F, Tanaka M, Tamada Y, Tanaka Y, Nilaver G & Ibata Y 1999 The Influence of Salt Loading on Vasopressin Gene Expression in Magno- and Parvocellular Hypothalamic Neurons: an Immunocytochemical and in Situ Hybridization Analysis. Neuroscience 89 515-523.
3. Atchley DP & Eckel LA 2005 Fenfluramine Treatment in Female Rats Accelerates the Weight Loss Associated With Activity-Based Anorexia. Pharmacology & Biochemisry of Behaviour 80 273-279.
4. Attia E, Wolk S, Cooper T, Glasofer D & Walsh BT 2005 Plasma Tryptophan During Weight Restoration in Patients With Anorexia Nervosa. Biology of Psychiatry 57 674-678.
5. Aulakh CS, Wozniak KM, Hill JL & Murphy DL 1988 Long-Term Imipramine Treatment Differentially Affects Fenfluramine-Induced Suppression of Food Intake and Locomotor Activity. Pharmacology & Biochemisty of Behaviour 31 97-101.
6. Bray GA & Greenway FL 1999 Current and Potential Drugs for Treatment of Obesity. Endocrine Reviews 20 805-875.
7. Broocks A, Schweiger U & Pirke KM 1991 The Influence of Semistarvation-Induced Hyperactivity on Hypothalamic Serotonin Metabolism. Physiology of Behaviour 50 385-388.
8. Burden VR, White BD, Dean RG & Martin RJ 1993 Activity of the Hypothalamic-Pituitary-Adrenal Axis Is Elevated in Rats With Activity-Based Anorexia. Journal of Nutrition 123 1217-1225.
9. Campbell DA, Sundaramurthy D, Markham AF & Pieri LF 1998 Lack of Association Between 5-HT2A Gene Promoter Polymorphism and Susceptibility to Anorexia Nervosa. Lancet 351 499.
10. Casper RC, Schoeller DA, Kushner R, Hnilicka J & Gold ST 1991 Total Daily Energy Expenditure and Activity Level in Anorexia Nervosa. American Journal of Clinical Nutrition 53 1143-1150.
11. Choi S, Jonak EM, Simpson L, Patil V & Fernstrom JD 2002 Intermittent, Chronic Fenfluramine Administration to Rats Repeatedly Suppresses Food Intake Despite Substantial Brain Serotonin Reductions. Brain Research 928 30-39.
12. Clifton PG, Lee MD & Dourish CT 2000 Similarities in the Action of Ro 60-0175, a 5-HT2C Receptor Agonist and D-Fenfluramine on Feeding Patterns in the Rat. Psychopharmacology (Berlin) 152 256-267.
13. Clifton PG, Lee MD, Somerville EM, Kennett GA & Dourish CT 2003 5-HT1B Receptor Knockout Mice Show a Compensatory Reduction in 5-HT2C Receptor Function. European Journal of Neuroscience 17 185-190.
14. Collier DA, Arranz MJ, Li T, Mupita D, Brown N & Treasure J 1997 Association Between 5-HT2A Gene Promoter Polymorphism and Anorexia Nervosa. Lancet 350 412.
15. Cone RD 1999 The Central Melanocortin System and Energy Homeostasis. Trends in Endocrinological Metabolism 10 211-216.
16. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD & Schaff HV 1997 Valvular Heart Disease Associated With Fenfluramine-Phentermine. New England Journal of Medicine 337 581-588.
17. Dourish CT 1995 Multiple Serotonin Receptors: Opportunities for New Treatments for Obesity? Obesity Research 3 Suppl 4 449S-462S.
18. Fletcher PJ 1988 The Effects of D-Fenfluramine on Saccharin Intake and Preference, and on Food and Water Intake. Pharmacology & Biochemistry of Behaviour 29 687-691.
19. Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C & Skovira K 2002 Reduced 5-HT2A Receptor Binding After Recovery From Anorexia Nervosa. Biology of Psychiatry 52 896-906.
20. Gibson EL, Kennedy AJ & Curzon G 1993 D-Fenfluramine- and D-Norfenfluramine-Induced Hypophagia: Differential Mechanisms and Involvement of Postsynaptic 5-HT Receptors. European Journal of Pharmacology 242 83-90.
21. Gorwood P, Ades J, Bellodi L, Cellini E, Collier DA, Di Bella D, Di Bernardo M, Estivill X, Fernandez-Aranda F, Gratacos M et al. 2002 The 5-HT(2A) -1438 G/A Polymorphism in Anorexia Nervosa: a Combined Analysis of 316 Trios From Six European Centres. Molecular Psychiatry 7 90-94.
22. Guy-Grand B 1995 Clinical Studies With Dexfenfluramine: From Past to Future. Obesity Research 3 491S-496S.
23. Hall JF & Hanford PV 1954 Activity As a Function of a Restricted Feeding Schedule. Journal of Comparative Physiology & Psychology 47 362-363.
24. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H et al. 2002 Activation of Central Melanocortin Pathways by Fenfluramine. Science 297 609-611.
25. Hillebrand JJ, de Rijke CE, Brakkee JH, Kas MJ & Adan RA 2005a Voluntary Access to a Warm Plate Reduces Hyperactivity in Activity-Based Anorexia. Physiology of Behaviour 85 151-157.
26. Hillebrand JJ, Kas MJ & Adan RA 2005b a-MSH Enhances Activity-Based Anorexia. Peptides 26 1690-1696.
27. Hillebrand JJG, Kas MJH, Scheurink AJW, van Dijk G & Adan RAH 2005c AgRP (83-132) and SHU9119 differently affect activity-based anorexia. European Neuropsychopharmacolgy (In press).
28. Hu X, Giotakis O, Li T, Karwautz A, Treasure J & Collier DA 2003 Association of the 5-HT2c Gene With Susceptibility and Minimum Body Mass Index in Anorexia Nervosa. Neuroreport 14 781-783.
29. Iovino M & Steardo L 1985 Meet of Substances Influencing Brain Serotonergic Transmission on Plasma Vasopressin Levels in the Rat. European Journal of Pharmacology 113 99-103.
30. Javed A, Kamradt MC, Van de Kar LD & Gray TS 1999 D-Fenfluramine Induces Serotonin-Mediated Fos Expression in Corticotropin-Releasing Factor and Oxytocin Neurons of the Hypothalamus, and Serotonin-Independent Fos Expression in Enkephalin and Neurotensin Neurons of the Amygdala. Neuroscience 90 851-8581.
31. Kas MJ, van Dijk G, Scheurink AJ & Adan RA 2003 Agouti-Related Protein Prevents Self-Starvation. Molecular Psychiatry 8 235-240.
32. Kaye WH, Ebert MH, Raleigh M & Lake R 1984 Abnormalities in CNS Monoamine Metabolism in Anorexia Nervosa. Archives of General Psychiatry 41 350-355.
33. Kaye WH, Gwirtsman HE, Gorge DT & Ebert MH 1991 Altered Serotonin Activity in Anorexia Nervosa After Long-Term Weight Restoration. Does Elevated Cerebrospinal Fluid 5-Hydroxyindoleacetic Acid Level Correlate With Rigid and Obsessive Behavior? Archives of General Psychiatry 48 556-562.
34. Kaye WH, Nagata T, Weltzin TE, Hsu LK, Sokol MS, McConaha C, Plotnicov KH, Weise J & Deep D 2001 Double-Blind Placebo-Controlled Administration of Fluoxetine in Restricting- and Restricting-Purging-Type Anorexia Nervosa. Biology of Psychiatry 49 644-652.
35. Kaye WH, Barbarich NC, Putnam K, Gendall KA, Fenstrom J, Fernstrom M, McConaha CW & Kishore A 2003 Anxiolytic Effects of Acute Tryptophan Depletion in Anorexia Nervosa. International Journal of Eating Disorders 33 257-267.
36. Kennett GA & Curzon G 1988 Evidence That MCPP May Have Behavioural Effects Mediated by Central 5-HT1C Receptors. British Journal of Pharmacology 94 137-147.
37. Kron L, Katz JL, Gorzynski G & Weiner H 1978 Hyperactivity in Anorexia Nervosa: a Fundamental Clinical Feature. Comprehensive Psychiatry 19 433-440.
38. Lee MD, Kennett GA, Dourish CT & Clifton PG 2002 5-HT1B Receptors Modulate Components of Satiety in the Rat: Behavioural and Pharmacological Analyses of the Selective Serotonin1B Agonist CP-94,253. Psychopharmacology (Berlin) 164 49-60.
39. Lee MD, Somerville EM, Kennett GA, Dourish CT & Clifton PG 2004 Reduced Hypophagic Effects of D-Fenfluramine and the 5-HT(2C) Receptor Agonist MCPP in 5-HT(1B) Receptor Knockout Mice. Psychopharmacology (Berlin) 176 39-49.
40. Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F & Hen R 1998 Absence of Fenfluramine-Induced Anorexia and Reduced C-Fos Induction in the Hypothalamus and Central Amygdaloid Complex of Serotonin 1B Receptor Knock-Out Mice. Journal of Neuroscience 18 5537-5544.
41. MacLean MR 1999 Pulmonary Hypertension, Anorexigens and 5-HT: Pharmacological Synergism in Action? Trends in Pharmacological Science 20 490-495.
42. Max MB 1994 Treatment of Post-Herpetic Neuralgia: Antidepressants. Annals of Neurology 35 S50-S53.
43. McCann UD, Yuan J, Hatzidimitriou G & Ricaurte GA 1997 Selective Serotonin Reuptake Inhibitors Dissociate Fenfluramine's Anorectic and Neurotoxic Effects: Importance of Dose, Species and Drug. Journal of Pharmacology & Experimental Therapy 281 1487-1498.
44. Mikkelsen JD, Jensen JB, Engelbrecht T & Mork A 1999 D-Fenfluramine Activates Rat Oxytocinergic and Vasopressinergic Neurons Through Different Mechanisms. Brain Research 851 247-251.
45. Mistlberger RE 1994 Circadian Food-Anticipatory Activity: Formal Models and Physiological Mechanisms. Neuroscience Biobehavior Reviews 18 171-195.
46. Nacmias B, Ricca V, Tedde A, Mezzani B, Rotella CM & Sorbi S 1999 5-HT2A Receptor Gene Polymorphisms in Anorexia Nervosa and Bulimia Nervosa. Neuroscience Letters 277 134-136.
47. Nijsen MJ, Croiset G, Stam R, Bruijnzeel A, Diamant M, De Wied D & Wiegant VM 2000 The Role of the CRH Type 1 Receptor in Autonomic Responses to Corticotropin- Releasing Hormone in the Rat. Neuropsychopharmacology 22 388-399.
48. Rieg TS, Maestrello AM & Aravich PF 1994 Weight Cycling Alters the Effects of D-Fenfluramine on Susceptibility to Activity-Based Anorexia. American Journal of Clinical Nutrition 60 494-500.
49. Roth JD & Rowland NE 1998 Efficacy of Administration of Dexfenfluramine and Phentermine, Alone and in Combination, on Ingestive Behavior and Body Weight in Rats. Psychopharmacology (Berlin) 137 99-106.
50. Routtenberg A & Kuznesof AW 1967 Self-Starvation of Rats Living in Activity Wheels on a Restricted Feeding Schedule. Journal of Comparative Physiology & Psychology 64 414-421.
51. Rowland NE & Carlton J 1986 Neurobiology of an Anorectic Drug: Fenfluramine. Progress in Neurobiology 27 13-62.
52. Saydoff JA, Rittenhouse PA, Carries M, Armstrong J, Van de Kar LD & Brownfield MS 1996 Neuroendocrine and Cardiovascular Effects of Serotonin: Selective Role of Brain Angiotensin on Vasopressin. American Journal of Physiology 270 E513-E521.
53. Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ & Baskin DG 2000 Central Nervous System Control of Food Intake. Nature 404 661-671.
54. Simansky KJ 1996 Serotonergic Control of the Organization of Feeding and Satiety. Behavioural Brain Research 73 37-42.
55. Simansky KJ & Nicklous DM 2002 Parabrachial Infusion of D-Fenfluramine Reduces Food Intake. Blockade by the 5-HT(1B) Antagonist SB-216641. Pharmacology & Biochemistry of Behaviour 71 681-690.
56. Sorbi S, Nacmias B, Tedde A, Ricca V, Mezzani B & Rotella CM 1998 5-HT2A Promoter Polymorphism in Anorexia Nervosa. Lancet 351 1785.
57. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF & Julius D 1995 Eating Disorder and Epilepsy in Mice Lacking 5-HT2c Serotonin Receptors. Nature 374 542-546.
58. van Tol HH, Voorhuis DT & Burbach JP 1987 Oxytocin Gene Expression in Discrete Hypothalamic Magnocellular Cell Groups Is Stimulated by Prolonged Salt Loading. Endocrinology 120 71-76.
59. Vickers SP, Clifton PG, Dourish CT & Tecott LH 1999 Reduced Satiating Effect of D-Fenfluramine in Serotonin 5-HT(2C) Receptor Mutant Mice. Psychopharmacology (Berlin) 143 309-314.
60. Vickers SP, Benwell KR, Porter RH, Bickerdike MJ, Kennett GA & Dourish CT 2000 Comparative Effects of Continuous Infusion of MCPP, Ro 60-0175 and D-Fenfluramine on Food Intake, Water Intake, Body Weight and Locomotor Activity in Rats. British Journal of Pharmacology 130 1305-1314.
61. Vickers SP, Dourish CT & Kennett GA 2001 Evidence That Hypophagia Induced by D-Fenfluramine and D-Norfenfluramine in the Rat Is Mediated by 5-HT2C Receptors. Neuropharmacology 41 200-209.
62. Vickers SP, Easton N, Webster LJ, Wyatt A, Bickerdike MJ, Dourish CT & Kennett GA 2003 Oral Administration of the 5-HT2 Creceptor Agonist, MCPP, Reduces Body Weight Gain in Rats Over 28 Days As a Result of Maintained Hypophagia. Pychopharmacology (Berlin) 167 274-280.
63. Walsh BT & Devlin MJ 1998 Eating Disorders: Progress and Problems. Science 280 1387-1390.
64. Westberg L, Bah J, Rastam M, Gillberg C, Wentz E, Melke J, Hellstrand M & Eriksson E 2002 Association Between a Polymorphism of the 5-HT2C Receptor and Weight Loss in Teenage Girls. Neuropsychopharmacology 26 789-793.
65. Wilckens T, Schweiger U & Pirke KM 1992 Activation of 5-HT1C-Receptors Suppresses Excessive Wheel Running Induced by Semi-Starvation in the Rat. Psychopharmacology (Berl) 109 77-84.